At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 13 enrolled
Drug / intervention
PTI-125, 100 mg tabletsdrug
Likely dose
PTI-125, 100 mg tabletsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2a, Open-label, Multiple Dose, Safety, Pharmacokinetic and Biomarker Study of PTl-125 in Mild-to-moderate Alzheimer's Disease Patients
In Brief
A Phase 2 clinical trial evaluating PTI-125, 100 mg tablets for Alzheimer Disease. Completed, enrolled 13 participants across 2 sites.
Detailed Summary
This is a Phase 2a, multi-center, open-label study of PTI-125 in mild-to-moderate Alzheimer's disease patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer Disease
CountriesUnited States
CollaboratorsNational Institute on Aging (NIA)
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedNov 2018
Enrollment StartMar 2019
Primary CompletionMay 2019
TodayJul 2026
First PostedNov 21, 2018
Enrollment StartMar 7, 2019
Primary CompletionMay 8, 2019
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 7.6 years ago
Interventions
PTI-125, 100 mg tabletsdrug
PTI-125, 100 mg tablets taken twice a day for 28 days